Potato extract inhibits lipase activity and ameliorates gut microbiome dysbiosis and weight gain in mice fed a high-fat diet

Dorsilla Anono Katimbwa1, Jinsung Ma1, Chang-Kil Kim2, Dongyup Hahn1 and Jinkyu Lim1*

Abstract
Curtailing the absorption of triglycerides (TGs) is a preferred pathway for treating obesity. Our previous study demonstrated that the water-soluble fraction from potato could inhibit the lipase activity of patatin, one of the major proteins in potato. This aqueous fraction was purified and concentrated by deproteination and reversed-phase chromatography to investigate the effectiveness against obesity. Biochemical analyses indicated that the fraction non-competitively inhibited pancreatic lipase (PLase) with a half-maximal inhibitory concentration of 10.17 µg/mL, and was named as potato-derived lipase inhibitory fraction (PI). Animal studies on C57BL/6 mice showed that in mice fed a high-fat diet (HFD), PI treatment resulted in reductions in body weight gain, adipose fat deposition, and liver TGs, and ameliorated the gut microbiome dysbiosis caused by HFD feeding; meanwhile, orlistat, a well-known lipase inhibitor, diverged the gut microbiome profile in mice fed a HFD. High resolution electron spray ionization-Orbitrap tandem mass spectrometry identified gallic acid, 4-hydroxybenzoic acid, and protocatechuic acid, which are known to have lipase inhibitory activities, in PI. However, these compounds could not reconstitute comparable specific inhibitory activity of PI inferring the existence of another inhibitory compound(s) to be identified in PI.

Keywords: Gut microbiome, Obesity, Pancreatic lipase inhibition, Potatoes (Solanum tuberosum L. tubers)

Introduction
According to the World Health Organization, the prevalence of obesity tripled from 1975 to 2016, with 1.9 billion adults and an estimated 41 million children less than 6 years old classified as either overweight or obese [1]. Obesity has been associated with an increased risk of disability and early mortality and an increased incidence of morbidities, such as cardiovascular disease, diabetes, cancer, non-alcoholic fatty liver disease [2], and gut microbiome dysbiosis, such as alterations in relative abundances of different bacterial phyla, specifically Bacteroidetes and Firmicutes [3, 4].

The primary driver of obesity is an energy imbalance caused by excessive calorie consumption, frequently through the consumption of calorie-dense, high-fat foods, combined with low-calorie expenditures. This phenomenon is exacerbated by the modern sedentary lifestyle, and, as such, the mitigation of fat absorption by inhibiting pancreatic lipase (PLase) is a principal research goal in the field of obesity treatment [5, 6].

Many different compounds and extracts from plant and microbial sources have been investigated and reported in the search for PLase inhibitors [7–9]. Among the identified natural substances with PLase inhibition activities, orlistat, a hydrogenated form of lipstatin originally isolated from Streptomyces toxytricini is one of the best-selling drugs under the trade name of Xenical (Roche, Basel, Switzerland) for the treatment of diet-induced obesity [10]. The success of orlistat has spawned research into identifying other enzyme inhibitors from natural sources
with fewer unpleasant or ameliorated side effects of orlistat, such as oily stools, flatulence, fecal urgency, and abdominal cramps [11].

Potatoes (Solanum tuberosum L.) contain approximately 5% protein—40% of which is from the patatin protein family [12]. Patatin primarily serves as a storage protein and is also a lipid acyl hydrolase that could lyse lipid and inhibit larval growth [13]. Our previous comparative analysis of the lipid acyl hydrolase activity of patatin in 14 different cultivars of potatoes suggested that lipase inhibition activities in potatoes among which the Sumi cultivar was chosen as the ideal candidate for evaluation of lipase inhibitor activity in potatoes. In the current study, we isolated and purified the lipase-inhibiting fraction from potato to characterize its mechanism of action and to assess its lipase inhibitory capacity in vitro with different fatty acid esters and triglycerides (TGs), as well as in vivo using obesity-induced C57BL/6 mice. Its amelioration effects on the dysbiosis of the gut microbiome in mice fed a high-fat diet (HFD) were also assessed. Furthermore, ion-exchange chromatography (IEC) and high-resolution tandem mass spectrometric analysis (MS/MS) were used to evaluate the active components within PI.

Materials and methods

Preparation of PI and identification of active components

The potatoes were peeled and shredded in a blender with distilled water at a ratio of 500 mL/kg potatoes to derive a slurry. The slurry was stirred using a magnetic stirrer for 1 h at room temperature (RT). The extract was filtered through cheesecloth and then centrifuged at 10,000×g for 20 min to remove the insoluble matter. The proteins were precipitated by adding 4 volumes of acetone and kept overnight at 4 °C. The sample was then centrifuged at 10,000×g for 20 min at 4 °C to pellet the precipitated patatin and specific proteins and polysaccharides. The supernatant was then decanted and vacuum-dried to 36 °C until the solvent was completely evaporated. Then, 1.0 g of the combined vacuum-dried extract from the butanol and ethyl acetate layers was dissolved in 100 mL of deionized water, and added to a glass column pre-packed with 100 g of C18 resin (RS Tech, Chungcheongbuk-do, South Korea), equilibrated with deionized water. Upon loading the sample and collecting the flow-through, the column was washed with 600 mL of deionized water, then eluted with a stepwise gradient starting from 100 mL of 10% methanol up to 100% methanol with an increment of 10% at each step. The flow-through and washed fractions, which contained most of the PIase inhibitory activity, were then lyophilized, dissolved in a minimum amount of deionized water (approximately 1 mL/600 mg of the residue), designated as potato-derived lipase inhibitory fraction, PI, and kept frozen at −80 °C.

Biochemical assays for lipase inhibition

p-Nitrophenylbutyrate substrate

The inhibitory effect of PI on pancreatic lipase was assessed based on a previous method with slight alterations using p-nitrophenylbutyrate (p-NPB) (Sigma-Aldrich, St. Louis, MO, USA) as a substrate [16] by measuring the absorbance at 410 nm using a Sunrise microplate reader (Tecan Group AG, Männedorf, Switzerland). PIase, procured from Sigma-Aldrich (St. Louis, MO, USA), was freshly prepared and pre-warmed at 37 °C for 10 min before each assay by dissolving it in 100 mM of sodium phosphate buffer (pH 7.4) to make a PIase suspension with a final concentration of 15 mg/mL. Then, 10 μL of various concentrations of sample (dissolved in deionized water) were mixed with 40 μL of 0.1 M sodium phosphate buffer (pH 7.4), 10 μL of 20 mM p-NPB (dissolved in absolute ethanol) and deionized water for a final volume of 180 μL/well. For the inhibitory control, 10 μL of orlistat (1 mg/mL in DMSO) was used. Next, 10 μL of the PIase suspension was added into the assay mixture and the reaction plate was then incubated at 37 °C for 20 min, and absorbance was measured as previously described. This experiment was conducted in duplicate.

4-Methylumbelliferyl oleate substrate

Plase inhibition by PI using a fluorescent substrate, 4-methylumbelliferyl oleate (4-MUO), was assessed [17]. The assay was set up in triplicate in an opaque 96-well plate; 4-MUO was dissolved in a 13 mM Tris buffer, 150 mM sodium chloride and 1.3 mM calcium chloride solution to make a 0.5 mM suspension. Each well contained 40 μL of 0.05 M Tris buffer (pH 8), 10 μL of
PI and 10 µL of the prepared 4-MUO suspension, mixed with 10 µL of pre-warmed PLase suspension (15 mg/mL). Deionized water was then added for a total volume of 100 µL. Orlistat (1 mg/mL in DMSO) was again used as an inhibitory control. The assay mixture was incubated at 37 °C for 20 min and then stopped by adding 100 µL of 0.1 M sodium citrate (pH 4). Fluorescence was measured on an Infinite F200 PRO fluorescence microplate reader (Tecan Group AG, Mannerdorf, Switzerland) at an excitation wavelength of 360 nm and an emission wavelength of 460 nm. The specific lipase inhibition was calculated by dividing the difference between total and residual lipase activity with the total activity (negative control) for 10 µL of the sample [18, 19].

**Triglyceride substrate**

The commercial Lipoprotein Lipase (LPLase) Activity Assay Kit (Cell Biolab Inc., San Diego, CA, USA) was adopted to analyze the inhibition of pancreatic lipase by PI using a fluorogenic triglyceride analog as the substrate. TG hydrolase activity was assayed in accordance with the manufacturer’s instructions. Both LPLase and PLase were assayed against the inhibitor, PI, at stepped volumes of 1, 5 and 10 µL of 200 µg/mL to assess inhibition. As a positive control, 10 µL of orlistat (1 mg/mL of DMSO) was also used.

**Kinetics, dose–response and storage stability analysis**

The inhibition kinetics of PI was assessed at concentrations of 0.99, 3.98, and 15.94 µg/mL, which were each mixed with 4-MUO at concentrations of 0.447, 0.669, 1, 1.5, 2.27, and 3.4 mM. Orlistat was also used for comparison at concentrations of 0.0048, 0.0024, and 0.012 µg/mL. Furthermore, 40 µL of 0.05 M Tris buffer (pH 7.4), 10 µL of PLase (15 mg/mL), and deionized water were added to each well to bring the total reaction volume to 100 µL. The plate was incubated at 37 °C with shaking at 60 rpm. Readings were taken every 2 min for fluorescence at 360 nm excitation and 460 nm emission a total of 10 times. The inhibition mechanism was analyzed by Lineweaver–Burk double reciprocal plotting of the enzyme reaction velocity (1/V) against substrate concentrations (1/S) [20].

Dose–response analysis of PI took place at the final concentration of 0.025, 0.1, 0.4, 1.56, 6.25, 25, and 100 µg/mL. Orlistat was also used at the same concentrations as a positive control. The inhibitor concentrations were prepared and tested for percentage inhibition using 4-MUO as a substrate, as described above. The resultant values were then converted to % inhibition and plotted against the inhibitor concentration. After plotting the data, the resultant dose’s logarithmic function versus the PLase activity (%) curve was obtained from least-squares regression to calculate the IC50.

**Determination of PI composition**

Anion-IEC was used for further purification of PI before MS/MS analysis; 95.3 mg/mL of PI dissolved in 5 mM ammonium acetate was added to the DEAE-Sepharose column (Sigma-Aldrich, St. Louis, MO, USA) equilibrated using the same buffer. The column was then step-wise eluted using 3 mL of the following solvents; 0.01 M, 0.01 M, 0.1 M, and 1 M formic acid. The eluents were collected separately, neutralized, and assayed for lipase inhibitory activity using 4-MUO as a substrate. The active fraction from the anion-IEC was concentrated and analyzed using a Q-Exactive quadrupole Orbitrap tandem mass spectrometer with negative (−) electrospray ionization (ESI). Then, 0.15 mg/mL of the active eluent dissolved in methanol/water (70:30 v/v) was used for the MS/MS analysis. The sample flow rate into the ionizer was 10 µL/min. The Orbitrap MS/MS was set as follows: mass resolution power (FWHM) 140,000 at m/z 200, spray voltage of 4.50 kV, capillary temperature of 300 °C, S-lens R level of 50 V, mass range of m/z 100–1000, and collisional energy of 10–30 eV.

A spectral interpretation was performed using software with an automated peak-picking algorithm. The calibrated peaks with S/N > 6 were extracted and assigned to chemical formulas (mass error within 1.5 ppm) using said software [21].

The compounds identified by MS/MS were cross-referenced with published works and analyzed for lipase inhibitory activity using 4-MUO as a substrate. Analysis of the relative abundance of the compounds singled out by published works was carried out by HPLC using a reversed-phase (C18) column (Acclaim™ Polar Advantage II—4.6 × 250 mm, particle size, 5 μm, Thermo Scientific, San Jose, CA, USA). The column temperature was maintained at 25 °C. The mobile phase consisted of 10% methanol, 90% water and 0.1% trifluoroacetic acid, infused at a flow rate of 1 mL/min. The sample, in an injection volume of 10 µL, was separated in the isocratic mode using a UV detector at a wavelength of 274 nm. The eluted peaks were collected, lyophilized and assayed for lipase inhibitory activity.

**Animals and diet**

The experiments were performed in compliance with the guidelines of the Ethics and Animal Welfare of Kyungpook National University and were approved by the Institutional Review Board (KNU-2019-0034-1). A total of 40 5-week-old male C57BL/6 mice were obtained from Orient-Bio Inc. (Seongnam-si, Gyeonggi-do, Korea). Research diets were procured from Research Diet (New
Brunswick, NJ, USA). The mice had ad libitum access to water and chow during the first week of acclimatization. They were maintained under controlled conditions of 23±1 °C and light–dark periods of 12 h. They were then split into four groups of 10 each: normal diet (ND) (D12450J, 10% kcal from fat), high-fat diet (HFD) (D12492, 60% kcal from fat), HFD with orlistat, and HFD with PI. Orlistat-treated mice received 200 µg of orlistat per kg of diet, while those treated with PI received 5 g of PI per liter of drinking water based on the IC50 ratio of the two treatments, i.e., 1:21 (Orlistat/PI). PI was added to the drinking water because it is hygroscopic and rendered the diets too soft to supplement in this fashion. The treatment period was 8 weeks, after which clinical tests were performed. The mice were then euthanized by cervical dislocation or CO2 exposure, followed by organ and blood sample collection. Fecal samples were collected weekly for each group.

**Glucose and insulin tolerance tests**

At the end of the 8-week treatment period, biochemical assays were conducted on all animals before euthanasia. A fasting glucose measurement was taken after a 6 h daytime fast, followed by an intraperitoneal (IP) glucose tolerance test (IPGTT) via an IP injection of glucose of 1.5 g/kg body weight, and an IP insulin tolerance test (IPITT) via an IP injection of insulin of 1 U/kg body weight. Blood glucose was measured using an SD Glucometer (SD Biosensor Inc., Suwon, Gyeonggi-do, Korea) on blood collected from the tip of the tail vein.

**Body weight, organ and abdominal fat measurements**

The mice were weighed once per week until sacrifice. Organs, including the liver and cecum, and epididymal and perirenal fat were dissected from the mice after sacrifice, weighed, and stored promptly in sterile snap cap tubes at −80 °C until further processing and analysis.

**Serum biochemistry and liver and fecal TG analysis**

Blood biochemistry and C-reactive protein levels were analyzed at the Laboratory Animal Center of the Daegu-Gyeongbuk Medical Innovation Foundation (Daegu, Korea). Interleukin-6 (IL-6) in the blood was analyzed by an ELISA kit by following the manufacturer’s instructions. TGs in the liver tissues and fecal samples were extracted by adding 800 µL of HPLC-grade acetone to 150–350 mg of the sample [22]. In brief, samples were lysed until full homogenization. The homogenized sample-acetone mixtures were then incubated with agitation at RT overnight. The mixture was then centrifuged at 10,000×g for 10 min at RT and the supernatant was removed and dried in a speed vacuum. The lipid extract was kept in aliquots (50 µL) and stored at −80 °C. Hepatic and fecal TG determinations were completed using a TG-S assay kit purchased from Asan Pharm. Co. (Suwon, Gyeonggi-do, Korea) by following the manufacturer’s instructions. The TG content was standardized to concentration (mg/dL) per milligram of liver tissue or fecal sample.

**Microbiome analysis by 16S sequencing**

The cecal contents of 3 mice from each group (n=10) were thawed and extracted to assess genomic DNA therein using a QiAamp DNA Stool Mini Kit (Qiagen, Stockach, Germany). The sequencing of the bacterial 16S rDNA V3–V4 region was performed on an Illumina MiSeq platform by Chunlab Inc. (Seoul, Korea), followed by pipeline analysis for 16S-based microbial profiling. After quality filtration and merger of the raw data, the operational taxonomic units (OTUs) were clustered according to the methods devised by Rideout et al. [23] and annotated against an in-house EZBioCloud 16S rRNA database by the USEARCH program, with a ≥ 97% similarity cut-off after normalizing the gene copy number and the number of reads to a maximum of 41,170 reads. The raw data was then visualised and analysed for alpha-diversity (Shannon and Simpson indexes), beta-diversity and principal component analysis (PCA) via the interactive web services provided by ChunLab [24].

**Preparation of cecal extracts for gas chromatography–mass spectrometry (GC–MS)**

Approximately 0.1 g of frozen cecal content was placed in a 20 mL glass vial and dissolved in 10 mL of water. The sample was maintained at 70 °C for 10 min. Then, a Solid Phase MicroExtraction 50/30 µm fiber assembly with a divinylbenzene/carboxen/polydimethylsiloxane coating (Supelco, Bellefonte, PA, USA) was plugged in and the sample was incubated at 70 °C for 30 min to allow the absorption of volatile short-chain fatty acids (SCFAs) [25]. After incubation, the fiber was removed and placed in a GC–MS auto-sampler.

**SCFA analysis by GC–MS**

Total SCFA content was quantitatively analyzed by gas chromatography on an Agilent 7890 (Palo Alto, CA, USA) with a DB-FFAP chromatographic capillary column (30 m × 250 µm × 0.25 µm; Agilent) under the following conditions: Initial temperature of 50 °C for 1 min, heating to 240 °C at a rate of 10 °C/min, followed by maintenance at 240 °C for 30 min. The signal was then detected at 250 °C with a 70 eV ionization voltage using an Agilent 5975C mass selective detector (MSD) system. Acetic, propionic, and butyric acids were used as standards, and serial dilutions were plotted to generate a calibration curve of response to the concentration (µM).
The resultant values were standardized to µM per gram of cecal content based on the sample’s initially recorded mass.

Statistical analysis
In vitro and in vivo data are presented as mean ± standard error of the mean (SEM). Statistical analysis was done using SPSS statistics 22 software (SPSS Inc., Chicago, IL, USA). Data from the analyses were assessed for significant differences using one-way analysis of variance (ANOVA) and Duncan’s multiple range test. The statistical difference between ND and HFD-fed groups was determined by Student t-test. p < 0.05 was considered statistically significant.

Results and discussion
PI characteristics and lipase inhibition
The supernatant from the deproteination step was serially extracted using dichloromethane, ethyl acetate, and butanol. Ethyl acetate, butanol, and water phases showed the relative lipase inhibitory activities of 24.4, 18.9, and 56.7%, respectively, while the dichloromethane phase had no inhibitory activity (Table 1). Although water had the highest retention of lipase inhibitory components, as evidenced by its yield and lipase inhibition values, a substantial amount of the lipase inhibitory activity was extracted in butanol and ethyl acetate. These results suggest that the lipase inhibitory component contains polar functional groups enabling water solubility and hydrophobic moieties allowing solubility in non-polar solvents.

For further purification, the butanol- and ethyl acetate-phase extracts were preferable due to lower salt and protein concentrations than the water-phase extract. Extracts from the butanol and ethyl acetate phases were mixed and applied to a pre-packed C18 column equilibrated with deionized water, and then eluted with a stepwise increasing concentration of methanol. The assay for lipase inhibition using 4-MUO as a substrate and PLase as a target enzyme showed that most of the lipase inhibitory activity was found in the flow-through and wash fractions with 88 and 70% of recovery yields, respectively (Table 2); subsequent methanol eluents showed little activity (Additional file 1: Fig. S1). The flow-through fraction was freeze-dried, reconstituted in deionized water, and then designated as potato-derived lipase inhibitory fraction, PI.

The storage stability of PI was tested at various temperatures over a period of 4 weeks. The results (Additional file 1: Fig. S2) showed that the lipase inhibitory activity of PI persisted at high efficiency for 4 weeks at temperatures ranging from 4 to 37 °C.

To compare the lipase inhibition efficiency of PI according to the length of fatty acid chain, substrates with p-nitrophenyl as a chromophore ester-bonded to octanoate (C8), decanoate (C10), myristate (C14), or palmitate (C16) were incubated with PLase in the presence or absence of PI for 30 min, 1 h, and 24 h. Regardless of the chain length of the substrate, PI showed efficient lipase inhibitory ability for all of the tested substrates, and this inhibitory ability last even after 24 h of incubation (Additional file 1: Fig. S3).

To see if the inhibition efficiency of PI for PLase is applied to other types of lipases, such as, bacterial lipase, inhibition assays were performed by incubating bacterial lipase or PLase with changing concentrations of PI using triolein as a substrate. The results from the lipase inhibition assay indicated that PI and orlistat inhibited triglyceride breakdown by bacterial lipase and porcine PLase in a dose-dependent manner (Fig. 1b) with higher activities in PLase.

Lineweaver–Burk double reciprocal plotting was performed to determine the mechanism of inhibition of

---

### Table 1 Lipase inhibitory activities in the extracts of different solvent phases

| Extraction      | Volume of reconstituted extract (mL) | Specific inhibitory activity | Relative inhibitory activity (%) |
|-----------------|-------------------------------------|-----------------------------|---------------------------------|
| Dichloromethane | 15                                  | n.d.                        | 0                               |
| Ethyl acetate   | 15                                  | 0.58±0.0017                 | 24.4±1.28                       |
| Butanol         | 15                                  | 0.45±0.0018                 | 18.9±1.00                       |
| Water           | 35                                  | 0.58±0.0001                 | 56.7±2.46                       |

* The specific lipase inhibition was calculated by dividing the difference between the total and the residual lipase activity with the total lipase activity (negative control) for 10 µL of the sample. 4-Methylumbelliferyl oleate (4-MUO) was used as a substrate. Orlistat (positive control) revealed 100% inhibition at a concentration of 0.01 mg/mL.

* The relative inhibitory activity was calculated as a fraction of the inhibitory activity from the total activity in all different solvent phases.

* Not detected

### Table 2 Lipase inhibitory activities of the C18 column fractions

| Fraction          | Volume of reconstituted extract (mL) | Specific inhibitory activity | Yield (%) |
|-------------------|--------------------------------------|-----------------------------|-----------|
| Concentrated      | 100                                  | 0.50                        | 100       |
| C18 flow-through  | 50                                   | 0.88                        | 88        |
| C18 wash          | 50                                   | 0.70                        | 70        |

* The specific lipase inhibition was calculated by dividing the difference between the total and the residual lipase activity with the total lipase activity (negative control) for 10 µL of the sample. 4-MUO was used as a fluorescent substrate. Orlistat revealed 100% inhibition (positive control) at a concentration of 0.01 mg/mL.

* The yield was calculated as a relative inhibitory activity in each fraction compared by the total activity in the “concentrated extract”
lipase activity by PI. Plots with the same x-intercept (unaffected \( K_a \)), but different slopes and y-intercepts (varied \( V_{\text{max}} \)) suggest that PI is a non-competitive inhibitor (Fig. 2a), indicating that the hydrophilic and water-soluble active component(s) in PI could bind to the substrate or enzyme–substrate complex allosterically, thereby, preventing binding to the substrate. In contrast, orlistat inhibition occurs when it binds competitively [26] to the active site on the lipase enzyme. The potency of the inhibitory activity of PI was analyzed using 4-MUO lipase substrate. The resultant fluorescence data was first converted into %-inhibition and then plotted against the inhibitor concentration. The estimated IC\(_{50}\) of PI was 10.17 µg/mL (Fig. 2b), compared to 0.48 µg/mL for orlistat (Fig. 2c). From the comparison of the IC\(_{50}\) values of PI and orlistat, we can predict that PI has lower potency toward pancreatic lipase than orlistat in TG digestion is different. PI inhibits lipase activity non-competitively (Fig. 2a) in the small intestine and can be metabolized in the large intestine while orlistat inhibits pancreatic lipase and microbial lipase competitively and stays undegraded in the small and large intestines. Thus, the fecal TG contents of the HFD and HFDOrl mice are similar throughout the feeding period, while the HFDOrl group showed increased fecal TG content (Additional file 1: Fig. S4B). PI-treatment reduced perirenal fat in the mice fed a HFD at levels similar to those for the mice treated with orlistat or fed an ND. Similarly, the PI-treated mice showed a reduction in epididymal fat compared to the mice fed a HFD, but did not reach the level of the orlistat-treated mice, who showed lower epididymal fat than the mice fed an ND (Fig. 3b). The PI-treated mice presented with significantly less TG stored in the liver as compared to the mice fed a HFD (\( p=0.003 \)). The liver TG accumulation in the PI-treated mice was lowered to that of the mice fed an ND, and this ability was lower than that of the liver TG accumulation by the orlistat-treated mice (Fig. 3c). These findings

**PI supplementation effects on the mice fed a HFD**

During the 8-week experimental period, PI-supplementation in the mice fed a HFD was shown to reduce weight gain at a comparable rate to orlistat-treated group (Fig. 3a). PI-treatment was associated with lower final body weights, at an average of 29.8±2.5 g compared to 38.24±3.5 g of the control HFD group. This result was similar to orlistat-treatment, associated with a final average weight of 28.4±2.5 g. The reduction in body weight gain in the PI-treatment group was despite a similar trend in food intake as the HFD group (Additional file 1: Fig. S4A). However, the inhibitory mechanisms of PI and orlistat in TG digestion is different. PI inhibits lipase activity non-competitively (Fig. 2a) in the small intestine and can be metabolized in the large intestine while orlistat inhibits pancreatic lipase and microbial lipase competitively and stays undegraded in the small and large intestines. Thus, the fecal TG contents of the HFD and HFDOrl mice are similar throughout the feeding period, while the HFDOrl group showed increased fecal TG content (Additional file 1: Fig. S4B). PI-treatment reduced perirenal fat in the mice fed a HFD at levels similar to those for the mice treated with orlistat or fed an ND. Similarly, the PI-treated mice showed a reduction in epididymal fat compared to the mice fed a HFD, but did not reach the level of the orlistat-treated mice, who showed lower epididymal fat than the mice fed an ND (Fig. 3b). The PI-treated mice presented with significantly less TG stored in the liver as compared to the mice fed a HFD (\( p=0.003 \)). The liver TG accumulation in the PI-treated mice was lowered to that of the mice fed an ND, and this ability was lower than that of the liver TG accumulation by the orlistat-treated mice (Fig. 3c). These findings
suggest the lipase inhibitory activity of PI reduces the digestion of TGs in the intestine and truncates increased amount of stored TGs in the liver as a result of intake of a fatty diet in obese individuals [28].

**PI improved glucose homeostasis**

To investigate the effect of the supplementation of a HFD with PI on glucose metabolism in obese mice, we analyzed blood glucose levels after administering glucose in a fasted state or injecting insulin.

The fasting blood glucose level in the mice fed a HFD was significantly higher than that of the mice fed an ND (at time 0 of Fig. 4a). The elevated fasting blood glucose level in the mice fed a HFD was reduced to the level of the mice fed an ND by PI and orlistat treatments. Moreover, from IPGTT, both PI and orlistat treatment promoted glucose homeostasis (Fig. 4a) and reduced glucose intolerance, as evidenced by the reduction in the peak blood glucose and area under the curve (AUC) of glucose concentration, seen in the HFD group, to levels comparable to the ND group (Fig. 4a, c). Insulin sensitivity was improved, as well as blood glucose concentrations (AUC) modulated in the PI-treated HFD-fed mice, during the IPITT, to levels observed in the mice fed an ND and to similar levels as the orlistat-treated HFD-fed mice (Fig. 4b, d). These results indicate that PI treatment better improves glucose homeostasis compared to an untreated HFD.

**Changes in serum biochemical indicators by PI treatment**

Dietary supplementation of PI to the mice fed a HFD, although markedly lowered the levels of the serum lipid biochemical markers, did not significantly impact the serum levels of TGs, total cholesterol, high-density lipoprotein (HDL), and low-density lipoprotein (LDL) due to the fluctuations among individuals per group, while significantly lower levels were detected in the ND and orlistat-HFD groups (Table 3). Fluctuations in blood TG levels within groups also precluded the assessment of differences among all four mice groups, which may have been erroneous due to the sample size (Table 3).
with HFD-induced obesity [30, 31]. In this study, plasma CRP level is higher in the HFD group than in the ND group as expected. However, the plasma CRP level is significantly lower in HFDOrl than in the ND group (Fig. 4d), although the perirenal fat and liver TGs are higher in HFDOrl than in ND (Fig. 3b, c). As the body weight gaining of the HFDOrl mice in 3-month period is comparable to that of the ND mice (Fig. 3a), the decreased level of CRP in the HFDOrl mice can be explained from considering the reports, which showed that elevation of plasma CRP level is highly associated with body-mass index (BMI) [32, 33]. The prolonged supplementation of orlistat to HFD from the beginning of the feeding with HFD for 8 weeks might be another responsible factor for the lowered CRP level.

The plasma level of IL-6 in the HFDPI group is lower compared to those of the groups of ND, HFD, and HFDPI, among which the IL-6 levels are not significantly different (Fig. 4e). The highest caecal SCFA level in the HFDPI mice among other groups (Table 4) can be associated with the lowered IL-6 because SCFA suppress inflammatory signaling in intestinal cells [34, 35].

It has been known that plasma levels of C-reactive protein (CRP) and IL-6 are highly associated with the progress of obesity. Increased pro-inflammatory cytokine production by T cells and macrophages is associated with an increased risk of diabetes, hypertension, and cardiovascular disease [29]. CRP, an important marker for vascular inflammation, and IL-6, which has intrinsic pro-inflammatory activity and significantly correlates to excess visceral adiposity, were measured as proxies for inflammation, and a reduction in their levels suggests reduced insulin resistance normally associated
Liver toxicity was assessed by a histology staining. H&E staining of the liver tissues indicated that the lipid droplets were significantly observed in the HFD group (Additional file 1: Fig. S5). In contrast to the HFD group, no significant macrovesicular steatosis was observed in other groups.

**PI attenuated gut microbiota dysbiosis**

To assess the impact of PI in high fat diet fed mice on gut microbiota at the end of 8-week feeding and treatment period, analysis of 16S RNA sequencing using next generation sequencing (NGS) technology was performed in cecal samples from 3 mice from each group obtained immediately after sacrifice.

α-Diversity, as assessed by the Shannon index (Fig. 5a), did not vary significantly among the mice fed an ND, HFD, or HFD-PI, but was significantly lower in the HFD-orlistat group ($p = 0.05$). For the Chao1 index of species richness index (Additional file 1: Fig. S6A), the ND group had the highest value, followed by the PI-treated and HFD groups; the orlistat-treated group had the lowest value. This same trend was upheld in the number of species observed for each group (Additional file 1: Fig. S6B). Low α-diversity is related to reduced feed efficiency [36] which could explain, at least in part, the reduced body weight gain in the orlistat-treated group. The PI-treated group showed similarity to the ND group in α-diversity, indicating a reduction from the levels observed in the HFD group. However, this reduction was not statistically significant as in the orlistat-treated group.

The microbiota, as relative phyla abundances, for the individuals (n = 3) in the four groups are represented in Fig. 5c. The present data show that the cecal microbiota of the mice were dominated by Bacteroidetes, Firmicutes, and Proteobacteria with other minor phyla (Deferribacteres, Cyanobacteria, Tenericutes, and Verrucomicrobia, among others). Although it is not statistically significant due to the data fluctuation, the HFD group was found to have a higher Firmicutes to Bacteriodes (F/B) ratio (0.92 ± 0.37) than the ND group (0.82 ± 0.22). The treatment with PI in the mice fed a HFD (0.89 ± 0.06) was associated with reduced F/B ratios similar to those of the mice fed an ND (Fig. 5b). Although orlistat treatment in the mice fed a HFD was also associated with a decreased F/B ratio, the orlistat microbiome profile diverged from that of the mice fed an ND, most significantly, the relative abundance of Proteobacteria in orlistat group was 48.97 ± 2.5% which was highest among the four cohorts (Fig. 5d). An increased abundance of Proteobacteria has been correlated with inflammatory bowel disease, potentially because of changes in transit time [37]. A previous murine model study found a link between gut microbial dysbiosis and obesity development [38], characterized by an increase in Enterobacteriaceae, particularly in the γ-Proteobacteria class. This increase has been associated with the gut inflammation that accompanies a dramatic reduction in Bacteriodes abundance and an increase in Firmicutes abundance [39]. Contrary to this, our results indicated that the PI treatment directly reduced the F/B ratio in the mice of a HFD. This would align with the current scientific consensus that many foods and dietary components can affect gut microbiota compositions.

PI treatment was also associated with higher relative abundances of Lachnospiraceae and Ruminococcaceae taxa compared to orlistat treatment in the mice fed a HFD (Fig. 5d). Ruminococcaceae is a member of the phylum Firmicutes in Clostridia cluster XIVa and was higher in the PI-treated mice than in the orlistat-treated mice. The Ruminococcaceae family also contains several butyric acid-producing bacteria with anti-inflammatory properties [40]. Our results also showed increases in other taxa members associated with the orlistat treatment but not PI treatment, including Clostridia and Enterobacteriaceae (Fig. 5d). Proteobacteria’s significant increase in the orlistat-treated mice fed a HFD suggests gut microbiota dysbiosis, as this phylum is overrepresented in obese children [41]. These findings, combined with observed higher abundances of Clostridia and Enterobacteriaceae and with PCA of microbial profiles (Fig. 6) in orlistat versus PI, indicate that while the competitive inhibitor of please, orlistat, does reduce the amount of TGs absorbed from the diet, it also contributes to gut dysbiosis [42].

Among the adverse effects of orlistat, such as oily stools, urgent defecation, diarrhea, and abdominal pain [43], diarrhea and abdominal pain might be related to the cecal predominance of Proteobacteria and Enterobacteriaceae (Fig. 5d) and consequently reduced diversity in microbiota and F/B ratio (Fig. 5b, c) [44, 45]. The gut...
2.2 Observations

2.4 ND HFD HFDOrl HFDPI

2.6

2.8

3.0

3.2

3.4

3.6

3.8

4.0

F/B ratio

a b
d

c

0

0.2

0.4

0.6

0.8

1.0

1.2

1.4

ND HFD HFDOrl HFDPI

F/B ratio

Bar plots showing the relative abundance of different bacterial groups under ND, HFD, HFDOrl, and HFDPI conditions. The x-axis represents different dietary interventions, and the y-axis shows the percentage of relative abundance.

Diversity plots comparing the bacterial abundance across ND, HFD, HFDOrl, and HFDPI conditions. The x-axis represents different bacterial groups, and the y-axis shows the percentage of relative abundance.

Taxonomic relative abundance plots for Proteobacteria, Lachnospiraceae, Runinococcaceae, Clostridium, and Enterobacteriaceae under ND, HFD, HFDOrl, and HFDPI conditions. The x-axis represents different dietary interventions, and the y-axis shows the percentage of taxonomic relative abundance.

* indicates statistical significance compared to ND.
microbiota dysbiosis exerted by an-absorbed TGs by the competitive lipase inhibitor, orlistat, could be improved by water soluble lipase inhibitor, PI, which can be metabolized in the gut and improve the diversity and restore F/B ratio to the level of ND (Fig. 5a–c).

No significant changes in lactic acid-producing bacteria such as *Bifidobacterium*, *Lactobacillus*, and *Lactococcus* were observed following treatment with PI or orlistat, nor were changes observed in other human gut taxa that are known to be beneficial to human health [38, 39], such as *Prevotella*, *Faecalibacterium*, *Bacteroides*, and *Akkermansia* (Additional file 1: Fig. S7).

The microbial profiles of the four groups were then analyzed for β-diversity, as measured by PCA of genera without unclassified OTUs, using the UniFrac distance matrix (Fig. 6). The results indicate that PI treatment in the mice fed a HFD increased their microbial profile's similarity to that of the mice fed an ND. In alignment with previous results, the orlistat-treated mice presented with a completely different profile from all the other groups; it occupied a different quadrant from them, indicating increased gut microbiome disruption specific and potentially directly linked to the orlistat treatment.

Inhibition of PLase activity by orlistat resulted in an increased concentration of fat retained in the gut, as seen in the significantly larger size of cecal content. This may be the stimuli for the significant change in the microbial profile. In contrast, PI that was shown to contain hydrophilic compounds that the gut microbiota can metabolize, resulting in a gut microbiome profile that was more similar to that of the mice fed an ND. The use of lipase inhibitors that can be degraded by microbiota may therefore provide a pathway for reducing the microbial alterations caused by unabsorbed TGs in the large intestine.
PLI increases colon microbial production of SCFAs
SCFAs are end products of the colonic microbial fermentation of dietary metabolites [46]. Acetic acid, butyric acid, and propionic acid are common SCFAs produced by commensal gut microbiota to reduce the pH of the intestinal environment, thereby facilitating the proper structure of intestinal flora, influencing the growth and differentiation of colonicocytes, and helping prevent colon cancer [47, 48]. Therefore, we analyzed the cecal contents of the mice from each group (n = 4) to assess concentrations therein. The PI treatment increased all three SCFAs compared to the orlistat treatment and no treatment HFD groups. The SCFA contents in the ceca of HFD-PI group were comparable or higher than those in the ND group. The acetic acid content was the highest (94.10 ± 8.71 μM per gram of cecal content) among groups; the propionic acid content was comparable to the ND group (58.18 ± 12.0 μM per g of cecal content); the butyric acid content was the highest (58.25 ± 17.4 μM per g of cecal content) among groups (Table 4). The amounts of acetic acid and butyric acid in the ceca of the HFD-PI group were higher than those in the ND group, suggesting an enhanced barrier function of the intestinal epithelia [49] and reduced inflammation indicated by reduced IL-6 in the blood (Fig. 4e).

Approximately 90% of the propionate produced in the colon enters the liver and decreases the lipid content by altering liver metabolic processes [50]. Therefore, the observed dramatic decrease in TGs in the liver of the PI-treated mice fed a HFD could be explained, at least in part, by significantly higher amounts of propionic acid being produced by gut microbiota.

The metabolism of PI in the intestine may also have been responsible for the increased SCFA content in the ceca by directly altering the microbial profile as a prebiotic or acting as a substrate for SCFA production [51].

The results of this study indicate that PI treatment can alleviate obesity and its associated health consequences in mice fed a HFD, likely by lowering TG absorption and the inflammatory cytokine profile and attenuating gut dysbiosis.

**Lipase inhibitory activity of the components of PI**
ESI-Orbitrap-MS/MS was used to elucidate the components of the PI. A total of 15 compounds were identified (Additional file 1: Table S1); among them; six emerged as possible candidates based on published works: gallic acid, quinic acid, shikimic acid, p-hydroxybenzoic acid, protocatechuic acid, and malic acid [52–54]. Pure forms were procured and assayed for lipase inhibitory activity to validate the lipase inhibitory activity of the identified compounds. Among the six, gallic acid, 4-hydroxybenzoic acid, and protocatechuic acid showed significant lipase inhibitory activity (Table 5). However, the activity was not comparable (less than 10%) to PI, even when all pure compounds were mixed (Table 5). Using bonded-C18 to analyze the relative abundance of the compounds showed that the majority of the materials in PI were not bound or were loosely bound to the bonded-C18 column and eluted between 2 and 6 min, and only gallic acid could be detected at very low concentrations (Additional file 1: Fig. S8A, B). The flow-through peaks were collected and assayed for lipase inhibitory activity against the pure compounds, and showed comparable (60.8%) activity of PI (Table 5). This reconstitution assay suggests that PI should contain more potent lipase inhibitory molecule(s) than the molecules tested in this study.

Some studies have identified that the aggregation of polyphenolic compounds manifests nonspecific inhibitory activities on PLase [55]. In this study, PI was extracted from potatoes using deionized water, and then further purified by collecting flow-through fraction from reversed-phase chromatography. The components in PI also showed a short retention time from a reversed-phase column, inferring the absence of phenolic compounds such as flavonoids [56]. Given the high polarity, there is less likelihood of the components of PI to aggregate and present PLase inhibitory activity nonspecifically. Furthermore, the identified phenolic acids such as gallic acid showed significantly low relative abundance and could not completely reconstitute the lipase inhibitory activity of PI (Table 5).

Further studies on the compounds within PI using other ionization methods and high-resolution MS/MS techniques are mandatory to help further elucidate PI inhibition mechanisms.

**Table 5 Specific lipase inhibition activities of compounds identified by MS/MS**

| Materials                             | Specific inhibitiona |
|---------------------------------------|----------------------|
| PI                                    | 8.45 ± 0.79          |
| Flow-through from bonded-C18          | 5.14 ± 0.42          |
| Gallic acid                           | 0.73 ± 0.019         |
| 4-Hydroxybenzoic acid                 | 0.43 ± 0.018         |
| Protocatechuic acid                   | 0.33 ± 0.019         |
| Mixture of all single compoundsb      | 0.82 ± 0.016         |

a The % inhibition values were divided by the masses (μg) of the materials used in the assay ± SD
b Gallic acid, 4-hydroxybenzoic acid, and protocatechuic acid were mixed with 17 μg each.

[Additional file 1: Table S1]
Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13765-021-00590-w.

Additional file 1: Fig. S1. Lipase inhibitory activities of 3 mL C18 column fractions, gradient eluted with 1 mL of water mixed with increasing concentrations of methanol (MeOH), after injection of 1 mL of 1.144 g/mL mix of butanol and ethyl acetate phase extract (ButOH/EA extract); 4-MUO used as a substrate. Each sample eluted with a percentage of methanol was evaporated then the volume adjusted back to 1 mL using deionised water. Fig. S2. Storage stability of PI at different temperatures. Fig. S3. Substrate specificity. Fig. S4. Average food intake in the four groups (A): Normal diet (ND), high fat diet (HFD), high fat diet with Orlistat treatment (HFDOrl) and high fat diet with PI treatment (HFDPI). As a result of dominant mouse aggression, there was reduced food intake between the 48th and 50th day especially in the HFDOrl group. (B) Fecal TG concentrations (HFDOrl) and high fat diet with PI treatment (HFDPI). As a result of dominant mouse aggression, there was reduced food intake between the 48th and 50th day especially in the HFDOrl group. (B) Fecal TG concentrations of mice fed on Normal diet (ND), high fat diet (HFD) and high fat diet with Orlistat treatment (HFDOrl). Fig. S5. H&E staining presents macrovesicular steatosis of the liver from the HFD group can be ameliorated by PI supplementation to HFD. Fig. S6. Effect of PI treatment (HFDPI) on α-diversity indices based on Chao1 species richness index (A) and number of identified species observed (B) as compared to mice fed on Normal diet (ND), high fat diet (HFD) and high fat diet with Orlistat treatment (HFDOrl). Fig. S7. Microbial taxonomic profile of most abundant genus (grouped). Fig. S8. Chromatogram of PI extract (A) and gallic acid (B) when analysed using reverse-phase HPLC-UV. Table S1. List of secondary metabolites of potato identified in negative ESI-MS/MS.

Abbreviations

4-MUO: 4-Methylumbelliferyl oleate; CRP: C-reactive protein; DMSO: Dimethyl sulfoxide; HCl: Hydrochloric acid; HDL: High-density lipoprotein; HFD: High-fat diet; HPLC: High-performance liquid chromatography; IC50: Inhibitor concentration at 50% substrate concentration; IL-6: Interleukin-6; IPGT: Intraperitoneal Injection Glucose Tolerance Test; IPITT: Intraperitoneal Injection Insulin Tolerance Test; LDL: Low-density lipoprotein; ND: Normal diet; p-NPB: para-nitrophenyl butyrate; TG: Triglycerides.

Acknowledgements

The authors are grateful to Dr. Jisu Oh from Dept. Food Biomaterials, KNU for her critical comments on the manuscript drafting. Dr. Kilsoo Kim from College of Veterinary Medicine, KNU, is acknowledged for helpful advice on the animal experiments.

Authors’ contributions

Animal experiment: DAK, JL. Conceptualization: JL, CKK, DH. Funding acquisition: JL. Investigation: DAK, JM. Method development: DAK, JM. DH. Supervision: JL. Writing and review and editing: DAK, JL. All authors have agreed to the published version of the manuscript. All authors read and approved the final manuscript.

Funding

This research was funded by a research grant from Korea National Research Foundation (NRF-2017R1D1A1B04035876).

Competing interests

The authors declare that they have no competing interests.

Author details

1 Department of Food Biomaterials, Kyungpook National University, 80 Daehak-Ro, Buk-Gu, Daegu, Korea. 2 Department of Horticulture Science, Kyungpook National University, Daegu, Korea.

Received: 29 November 2020 Accepted: 11 January 2021 Published online: 09 February 2021

References

1. WHO (2018) Obesity and overweight. Fact sheet. 311. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
2. Xie M, Chen G, Wan P, Dai Z, Zeng X, Sun Y (2019) Effects of dicaffeoylquinic acids from hesh kudingcha on lipid metabolism and intestinal microbiota in high-fat-diet-fed mice. J Agric Food Chem 67:171–183
3. Ley RE, Turnbaugh PJ, Klein S, Gordon JJ (2006) Human gut microbes associated with obesity. Nature 444:1022–1023
4. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JJ (2006) An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444:1027–1031
5. Mandle AD, Blaut M (2018) Do we choose control diets wisely? Trends Endocrinol Metabol 29:7
6. Liao W, Yin X, Li Q, Zhang H, Liu Z, Zheng X, Zheng L, Feng X (2018) Resveratrol-induced white adipose tissue browning in obese mice by remodeling fecal microbiota. Molecules 23:3356
7. Kumar P, Dubey KK (2015) Current trends and future prospects of lipstatin: a lipase inhibitor and pro-drug for obesity. R Soc Chem 5:86954–86966
8. Chanmee W, Chaicharoenpong C, Petsom A (2013) Lipase inhibitor from fruits of Solanum stramonifolium Jacq. Food Nutr Sci 4:554–558
9. Subandi LZ, Brotosudarmo THP (2019) Saponin from purple eggplant (Solanum melongena L.) and their activity. IOP Conf Ser Mater Sci Eng 509:012139
10. Franson K, Rossner S (2000) Fat intake and food choices during weight reduction with diet, behavioural modification and alipase inhibitor. J Intern Med 247:607–614
11. O’Donovan D, Horowitz M, Russo A, Feinle-Bisset C, Murolo N, Gentilec D, Wishart JM, Morris HA, Jones KL (2004) Effects of lipase inhibition on gastric emptying of, and on the glyceamic, insulin and cardiovascular responses to, a high-fat/carbohydrate meal in type 2 diabetes. Diabetologia 47:2208–2214
12. Barta J, Bártová V, Zdrahal Z, Sedo O (2012) Cultivar variability of patatin biochemical characteristics: table versus processing potatoes (Solanum tuberosum L.). J Agric Food Chem 60:4369–4378
13. James A, Strickland CO, Terence A (1995) Inhibition of Diabrofica larval growth by patatin, the lipid acyl hydrolase from potato tubers. Plant Physiol 109:667–674
14. Bollag DM, Edelstein SJ (1996) Protein methods. Wiley-Liss, New York
15. Pots AM, de Jongh HHJ, Gruppen H, Hamer RJ, Voragen AGJ (1998) Heat induced conformational changes of patatin, the major potato tuber protein. Eur J Biochem 252:66–72
16. Vorderwulbecke T, Kieslich K, Erdmann H (1992) Comparison of lipase by lipases by different assays. Enzyme Microb Technol 14:631–639
17. Nakai M, Fukui Y, Asami S, Toyota-Ono Y, Iwashita T, Shibata H, Mitsuokag T, Hashimoto F, Kiso Y (2005) Inhibitory effects of Ooling tea polyphenols on pancreatic lipase in vitro. J Agric Food Chem 53:4593–4598
18. Admassu H, Gasmalla MAA, Yang R, Zhao W (2018) Identification of bioactive peptides with α-amylase inhibitory potential from enzymatic protein hydrolysates of red seaweed (Porphyra spp.). J Agric Food Chem 66:4872–4882
19. Moreno-Córdovaa EN, Arzuvu-Flores AA, Valenzuela-Soto EM, García-Orozco KD, Wall-Medrano A, Álvarez-Parrilla E, Ayala-Zavala JF, Domínguez-Avila JA, González-Aguilar GA (2020) Gallotannins are competitive inhibitors of pancreatic lipase activity. Biophys Chem 264:106409
20. Jo YH, Kim SB, Liu Q, Do SG, Hwang BY, Lee MK (2017) Comparison of pancreatic lipase inhibitory isoflavonoids from unripe and ripe fruits of Cudrania tricuspidata. PLoS ONE 12:e01720169
21. Lee S, Cho Y, Kim S (2014) Development and application of a software tool for the interpretation of organic mixtures’ spectra—hydrogen deuterium exchange (STORM-HDX) to interpret APhi HDX MS spectra. Bull Korean Chem Soc 35:749–752
22. Tamer F, Ulug E, Akyol A, Nergiz-Unal R (2019) The potential efficacy of dietary fatty acids and fructose induced inflammation and oxidative stress on the insulin signalling and fat accumulation in mice. Food Chem Toxicol 135:110914
23. Rideout JR, He Y, Navas-Molina JA, Walters WA, Ursell LK, Gibbons SM, Chase J, McDonald D, Gonzalez A, Robbins-Pianka A, Clemente JC, Gilbert JA, Huse SM, Zhou HW, Knight R, Caporaso JG (2014) Subsampled open-reference clustering creates consistent, comprehensive OTU definitions and scales to billions of sequences. Peer J 2:e2454

24. Zarra P, Yilmaz P, Pruesse E, Glöckner FO, Ludwig W, Schleifer KH, Whitman WB, Ezubezy J, Amann R, Rosselló-Mora R (2014) Uniting the classification of cultured and uncultured bacteria and archaea using 16S rRNA gene sequences. Nat Rev Microbiol 12:635–645

25. Fiorini D, Boarelli MC, Gabbianelli R, Ballini R, Pacetti D (2016) A quantitative headspace-solid-phase microextraction-gas chromatography-flame ionization detector method to analyze short chain fatty acids in rat feces. Anal Biochem 508:12–14

26. Patil SG, Patil MP, Maheshwari VL, Patil RH (2015) In vitro lipase inhibitory effect and kinetic properties of di-terpenoid fraction from Calotropis procera (Aiton). Biocatal Agric Biotechnol 4:579–585

27. Alejandra I, Martinez-Gonzalez AI, Alvarez-Parrilla E, Díaz-Sánchez AG, de la Rosa L, Núñez-Gastélum JA, Vazquez-Flores AA, González-Aguilar GA (2017) In vitro inhibition of pancreatic lipase by polyphenols: a kinetic, fluorescence spectroscopy and molecular docking study. Food Technol Biotechnol 55:519–530

28. Hackl MT, Funniss C, Schuh CM, Krssak M, Carli F, Guerra S, Freudenthaler A, Baumgartner-Parzer S, Luger A, Zeyda M, Gastaldelli A, Buettern C, Scherer T (2019) Brain leptin reduces liver lipids by increasing hepatic triglyceride secretion and lowering lipoposining. Nat Comm 10:2717

29. Hammad MM, Abu-Farha M, Al-Taair A, Alam-Eldin N, Al-Sabah R, Shaban L, Al-Mulla F, Abubaker J, Rahman A (2020) Correlation of circulating ANGPTL5 levels with obesity, high sensitivity C-reactive protein and oxidized low-density lipoprotein in adolescents. Sci Rep 10:66330

30. Torres S, Fabensani E, Marquez A, Guaffin-Canoh P (2018) Adipose tissue inflammation and metabolic syndrome. Eur J Nutr 58:27–33

31. Park HS, Park JY, Yu R (2005) Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-α and IL-6. Diabetes Res Clin Pract 69:29–35

32. Park HS, Park JY, Yu R (2005) Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-α and IL-6. Diabetes Res Clin Pract 69:29–35

33. Blüher M, Fasshauer M, Tönjes A, Kratzsch J, Schön MR, Paschke R (2005) Effects of the modulation of pancreatic lipase under simplified intestinal conditions. PLoS ONE. https://doi.org/10.1371/journal.pone.0024853

34. McNabney SM, Henagan TM (2017) Short chain fatty acids in the colon and peripheral tissues: a focus on butyrate, colon cancer, obesity and insulin resistance. Nutrients 9:1348

35. McNabney SM, Henagan TM (2017) Short chain fatty acids in the colon and peripheral tissues: a focus on butyrate, colon cancer, obesity and insulin resistance. Nutrients 9:1348

36. Kel J, An Y, Cao B, Lang J, Wu N, Zhao D (2020) Orlistat-induced gut microbiota modification in obese mice. Evid Based Complementary Altern Med 2020:9818349

37. Schroll JB, Penninga EI, Gatzschke PC (2016) Assessment of adverse events in protocols, clinical study reports, and published papers of trials of orlistat: a document analysis. PLoS Med 13:e1002101. https://doi.org/10.1371/journal.pmed.1002101

38. Kang Z, Lu M, Jiang M, Zhou D, Huang H (2019) Proteobacteria acts as a pathogenic risk-factor for chronic abdominal pain and diarrhea in post-cholecystectomy syndrome patients: a gut microbiome metabolomics study. Med Sci Monit 25:7312–7320

39. Mahnic A, Breskvar M, Dzeroski S, Škok P, Pantar S, Rupnik M (2020) Distinct types of gut microbiota dysbiosis in hospitalized gastroenterological patients are disease non-related and characterized with the predominance of either enterobacteriaceae or enterococcus. Front Microbiol 11:120

40. Han F, Wang Y, Han Y, Zhao J, Han F, Song G, Jiang P, Mao H (2018) Effects of whole-grain rice and wheat on composition of gut microbiota and short-chain fatty acids in rats. J Agric Food Chem 66:6326–6335

41. Elamin EE, Mascllee AA, Dekker J, Pieters HJ, Jonkers DM (2013) Short-chain fatty acids activate AMP-activated protein kinase and ameliorate ethanol-induced intestinal barrier dysfunction in Caco-2 cell monolayers. J Nutr 143:1872–1881

42. McNabney SM, Henagan TM (2017) Short chain fatty acids in the colon and peripheral tissues: a focus on butyrate, colon cancer, obesity and insulin resistance. Nutrients 9:1348

43. Knudsen KEB, Laerke NH, Hedemann MS, Nielsen TS, Ingerslev AK, Nielsen DSG, Theil PK, Purup S, Hald S, Schioldan AG, Marco ML, Gregersen S, Hermansen K (2018) Impact of diet-modulated butyrate production on intestinal barrier function and inflammation. Nutrients 10:1499

44. Du H, Zhao A, Wang Q, Yang X, Ren D (2020) Supplementation of inulin with various degree of polymerization ameliorates liver injury and gut microbiota dysbiosis in high-fed obese mice. J Agric Food Chem 68:779–787

45. Havlik J, Marinello V, Gardyne A, Hou M, Mullen W, Morrison DJ, Preston T, Combet E, Edwards CA (2020) Dietary fibres differentially influence the production of phenolic acids from rutin in vitro fermentation model of the human gut microbiota. Nutrients 12:1557

46. Ou Y, Hou I-C, Fujita H, Yazawa K (2012) Association of interleukin-6, C-reactive protein, interleukin-10 and adiponectin plasma concentrations with measures of obesity, insulin sensitivity and glucose metabolism. Exp Clin Endocrinol Diabetes 120:534–537. https://doi.org/10.1055/s-2005-872851

47. Han F, Wang Y, Han Y, Zhao J, Han F, Song G, Jiang P, Mao H (2018) Effects of whole-grain rice and wheat on composition of gut microbiota and short-chain fatty acids in rats. J Agric Food Chem 66:6326–6335

48. McNabney SM, Henagan TM (2017) Short chain fatty acids in the colon and peripheral tissues: a focus on butyrate, colon cancer, obesity and insulin resistance. Nutrients 9:1348

49. Knudsen KEB, Laerke NH, Hedemann MS, Nielsen TS, Ingerslev AK, Nielsen DSG, Theil PK, Purup S, Hald S, Schioldan AG, Marco ML, Gregersen S, Hermansen K (2018) Impact of diet-modulated butyrate production on intestinal barrier function and inflammation. Nutrients 10:1499

50. Du H, Zhao A, Wang Q, Yang X, Ren D (2020) Supplementation of inulin with various degree of polymerization ameliorates liver injury and gut microbiota dysbiosis in high-fed obese mice. J Agric Food Chem 68:779–787

51. Ménendez-Salazar EO, Ortiz-López MG, Granados-Silvestre MDLA, Palacios-Gonzalez B, Menjivar M (2018) Altered gut microbiota and compositional changes in Firmicutes and Proteobacteria in Mexican undernourished and obese children. Front Microbiol. https://doi.org/10.3389/fmicb.2018.02494

52. Oi Y, Hou I-C, Fujita H, Yazawa K (2012) Association of interleukin-6, C-reactive protein, interleukin-10 and adiponectin plasma concentrations with measures of obesity, insulin sensitivity and glucose metabolism. Exp Clin Endocrinol Diabetes 120:534–537. https://doi.org/10.1055/s-2005-872851

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.